enGene Holdings Inc.
ENGN•NASDAQ•Healthcare•Biotechnology

About enGene Holdings

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORonald H. Cooper
Founded1999
Employees82
CountryCanada
Fiscal YearNovember - October

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
Share ClassClass A Shares

Contact Information

Websitewww.engene.com
Phone514 332 4888
Address
4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada

Corporate Identifiers

CIK0001980845
CUSIP46429B226
ISINCA29286M1059
SIC2836

Leadership Team & Key Executives

Ronald H. W. Cooper
President, Chief Executive Officer and Director
Dr. Anthony T. Cheung Ph.D.
Co-Founder and Chief Scientific Officer
David Ryan Daws
Chief Financial Officer and Head of Business Development
Dr. Alexander Nichols Ph.D.
Chief Strategy and Operations Officer
Joan Connolly
Chief Technology Officer
Lee G. Giguere
Chief Legal Officer and Corporate Secretary
Tara Place M.B.A.
Senior Vice President of Human Resources
Matthew Boyd
Chief Regulatory Officer
Jill Buck
Chief Development Officer
Amy Pott
Chief Global Commercialization Officer